Evotec Subsidiary Gets Contract With U.S. Defense Department for Orthopoxvirus Drugs
Provided by
Dow Jones
By Cecilia Butini
A U.S.-based subsidiary of German biotechnology company Evotec has won a contract with the Defense Department to develop drugs targeting orthopoxviruses, a family of viruses that includes smallpox and monkeypox, the company said Wednesday.
The contract, which was awarded to Seattle-based Just-Evotec Biologics, is worth up to $74 million and includes the rapid development of drug prototypes based on monoclonal antibodies. It will support the Defense Department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, the company said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 05, 2023 03:42 ET (07:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast